AI POWERED DRUG
REFORMUL ATION

Leveraging proprietary machine learning to reformulate essential medicines

Scroll Down Arrow

The Invisible Barrier in Modern Medicine

Today’s blockbuster therapeutics are designed for the average metabolism. But for 5 to 10% of the global population, the inactive ingredients (excipients) or standard delivery mechanisms in these drugs trigger severe genetic or metabolic adverse reactions.

Millions Left
Behind

Essential, life-saving therapies are rendered unusable for a massive segment of the population.

Clinical
Inefficiency

Adverse drug events cost the global healthcare system billions annually in extended hospital stays and alternative treatments.

Lost IP
Value

Proven Active Pharmaceutical Ingredients fail to reach their maximum market potential due to outdated formulation.

BY THE NUMBERS

0
Of patients in large preemptive PGx trials carried at least one actionable variant.
0
Emergency department visits for adverse drug events each year in the U.S. alone.
0
Estimated global cost of adverse drug events every year.
0
Reduction in adverse drug reactions achievable through genetic and metabolic-guided formulation.

Smarter Formulation. Safer Therapies.

Excipy’s algorithmic platform maps the complex interactions between active drugs, excipients, and human metabolic pathways. By predicting adverse reactions at the computational level, we engineer entirely new formulations of existing drugs, removing toxic triggers and mitigating side effects without altering the proven medical benefits.

Proudly backed by Bridgewest Ventures

A De-Risked Pathway to Market.

Traditional drug discovery takes over a decade and billions of dollars. Excipy operates on a fundamentally different timeline.

De-Risked APIs

Because we work with pre-approved, proven Active Pharmaceutical Ingredients, the clinical risk profile is drastically reduced.

Accelerated FDA Pathways

Our reformulations are designed to qualify for expedited regulatory routes (such as the FDA 505(b)(2) pathway), allowing us to bypass years of Phase I/II trials.

Scalable Architecture

Our ML models grow smarter with every formulation, creating a compounding advantage for our pipeline and our partners.

Redefining the Future of Pharma

We are building the foundational data infrastructure for next-generation drug formulation. Excipy is actively engaging with strategic investors, pharmaceutical partners, and world-class computational biologists to scale our pipeline.

CONTACT US
CONTACT US